| __timestamp | ADMA Biologics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 675200000 |
| Thursday, January 1, 2015 | 6745968 | 771800000 |
| Friday, January 1, 2016 | 8494742 | 1205500000 |
| Sunday, January 1, 2017 | 18092835 | 1146500000 |
| Monday, January 1, 2018 | 22502922 | 1125800000 |
| Tuesday, January 1, 2019 | 25910757 | 1166100000 |
| Wednesday, January 1, 2020 | 35050817 | 1175500000 |
| Friday, January 1, 2021 | 42896889 | 1111400000 |
| Saturday, January 1, 2022 | 52458024 | 1210100000 |
| Sunday, January 1, 2023 | 59020000 | 1274600000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. ADMA Biologics, Inc. and Perrigo Company plc, two prominent names, exhibit contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, ADMA Biologics saw a staggering increase of over 1,100% in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Perrigo Company maintained a more stable trajectory, with a modest 89% rise, indicating a focus on steady expansion and operational efficiency.
This divergence highlights the different paths companies can take in the competitive pharmaceutical sector. While ADMA's rapid increase suggests a focus on scaling operations, Perrigo's consistent spending underscores its commitment to sustainable growth. These insights provide a window into the strategic priorities shaping the future of these industry leaders.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Perrigo Company plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and Perrigo Company plc
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Breaking Down SG&A Expenses: Perrigo Company plc vs Xenon Pharmaceuticals Inc.
Perrigo Company plc or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Vericel Corporation
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Mesoblast Limited
Perrigo Company plc or MiMedx Group, Inc.: Who Manages SG&A Costs Better?